Finanzen von Cabaletta Bio, Inc. (CABA)CABACabaletta Bio, Inc.

Evaluating the bottom line, Cabaletta Bio, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -93.20%, provide a clear picture of how effectively CABA converts its operational activities into shareholder value.

In the context of the broader market, CABA competes directly with industry leaders such as RCKT and LCTX. With a market capitalization of $272.97M, it holds a leading position in the sector. When comparing efficiency, CABA's gross margin of N/A stands against RCKT's N/A and LCTX's 100.00%. Such benchmarking helps identify whether Cabaletta Bio, Inc. is trading at a premium or discount relative to its financial performance.

Cabaletta Bio has reported a series of negative net incomes, with the latest quarterly loss at -$51 million. The company has a current ratio of 5.79, indicating good short-term liquidity, but the overall financial health is concerning due to ongoing losses.